Repure Life Science Signs Joint Research Agreement with Kyung Nam Biopharma and Yonsei Health System
On May 27, Repure Life Science signed a joint research agreement with Kyung Nam Biopharma (CEO Hong, Sang-hyuk) and Yonsei University Health System (Director Yoon, Do-hum) to develop Coronavirus treatment.
This research aims at 'Development of antibodies for the treatment of COVID-19 based on immune proteins' and 'Screening of candidates for treatment of COVID-19 drugs using artificial intelligence (AI) and big data'.
The treatment with blood plasma of cured person was also used in the case of new virus infections such as Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), Ebola virus and Avian influenza.
At Yonsei Medical Center, the treatment with infusion of plasma of a cured person has firstly performed for critical COVID-19 patient . As the two patients who were treated were cured, the need for follow-up studies gathered.
On the day, the joint research and development agreement held at the Yonsei Medical Center General Hall was attended by Park, Eun-cheol, director of the Department of Medical Science and Research, Yonsei Medical Center, Hong, Sang-hyuk, CEO of Kyung Nam Biopharma, and Kim Yong-sang, CEO of Repure Life Science.
Park, Eun-cheol, director of the Department of Medical Science and Research, said, “Based on the research power and cooperation of the medical center, we will do our best to help to overcome the global crisis and present new possibilities.”